Symptom relief and improved quality of life in allergic rhinitis patients after transdermal allergy immunotherapy

Patients with allergic rhinitis (AR) experience side effects from pharmacotherapies and subcutaneous immunotherapy (SCIT). This prospective, observational study (IRB-approved, informed consent) assessed changes in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) scores and symptoms from baseline to 3 months for patients with AR using a transdermal allergy immunotherapy (TdIT) formulation.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: G. Plunkett, H. Legere, T. Smith, P. Hurwitz, J. Strader, D. Dietze Tags: P105 Source Type: research